Payment overview · 2025
General Payments
$256.90
10 reported records · 6 companies
Healthcare provider profile · identity verified
Julie C Cohen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKEWOOD, CO · NPI 1033377635
Verified facts
What the public records show
CMS Open Payments records show Julie C Cohen, MD received $256.90 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $93.68 | 36.5% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $58.65 | 22.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.89 | 16.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.72 | 9.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.34 | 7.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.62 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.90 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $93.68 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $93.68 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $93.68 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $58.65 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $58.65 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $58.65 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 84 |
| Losartan Potassium | Losartan Potassium | 215 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 46 |
| Trazodone Hcl | Trazodone Hcl | 136 | 38 |
| Gabapentin | Gabapentin | 117 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 32 |
| Lisinopril | Lisinopril | 104 | 29 |
| Meloxicam | Meloxicam | 101 | 32 |
| Omeprazole | Omeprazole | 100 | 37 |
| Eliquis | Apixaban | 94 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 27 |
| Spironolactone | Spironolactone | 85 | 25 |
| Donepezil Hcl | Donepezil Hcl | 79 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 23 |
| Furosemide | Furosemide | 75 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 21 |
| Tramadol Hcl | Tramadol Hcl | 65 | 14 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 15 |
| Mirtazapine | Mirtazapine | 57 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 19 |
| Estradiol | Estradiol | 52 | 21 |
| Metformin Hcl | Metformin Hcl | 49 | 18 |
| Potassium Chloride | Potassium Chloride | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 13 |
| Jardiance | Empagliflozin | 41 | 12 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | 14 |
| Acyclovir | Acyclovir | 38 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 11 |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Prednisone | Prednisone | 19 | 11 |
| Cephalexin | Cephalexin | 18 | 16 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.90 · 10 records | PFIZER INC. | ABRYSVO, COMIRNATY, ENTRESTO, EVENITY, LEQVIO, PREVNAR 20, PROLIA, QULIPTA, UBRELVY, Veozah, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error